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ABSTRACT
Introduction: The once-daily long-acting
muscarinic antagonist (LAMA) tiotropium and
once-daily long-acting b2-agonist (LABA)
olodaterol have been studied as a once-daily
fixed-dose combination (FDC) in patients with
chronic obstructive pulmonary disease (COPD).
Two large, 52-week, double-blind, parallel-
group studies in patients with moderate–very
severe COPD demonstrated that
tiotropium ? olodaterol significantly improved
lung function and symptoms versus the
monocomponents. This post hoc analysis
determined effects on lung function by prior
LAMA or LABA maintenance treatment and
initial disease severity.
Methods: 5162 patients were randomized and
treated with olodaterol 5 lg, tiotropium 2.5 lg,
tiotropium 5 lg, tiotropium ? olodaterol 2.5/
5 lg, or tiotropium ? olodaterol 5/5 lg (all once
daily via Respimat inhaler). Primary efficacy
(lung-function) end points were forced
expiratory volume in 1 s (FEV1) area under the
curve from 0 to 3 h (AUC0–3) and trough FEV1
responses (i.e., change from baseline). Pooled
data are presented for the following subgroups:
prior maintenance treatment with LAMA or
LABA, Global initiative for chronic Obstructive
Lung Disease (GOLD) 2 (predicted FEV1 50% to
\80%) and 3 (30% to\50%)/4 (\30%), sex, age,
and prior use of inhaled corticosteroids.
Results: Tiotropium ? olodaterol FDC
improved lung function over the
monocomponents in patients with GOLD 2
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and 3–4 disease, irrespective of prior LAMA or
LABA maintenance therapy; most comparisons
between FDCs and their respective
monocomponents were statistically significant
(P\0.05). FEV1 AUC0–3 and trough FEV1
responses for the individual treatments were
generally greater in patients with less severe
COPD at baseline.
Conclusions: Tiotropium ? olodaterol 5/5 lg
significantly improved FEV1 AUC0–3 and
trough FEV1 in all GOLD severity groups
compared to olodaterol 5 lg and tiotropium
5 lg alone, irrespective of whether patients had
received prior LAMA or LABA maintenance
treatment. Improvements from baseline in
lung function were generally greater in
patients with less severe disease.
Funding: Boehringer Ingelheim.
Trial registration: ClinicalTrials.gov numbers,
NCT01431274 and NCT01431287.
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muscarinic antagonists (LAMAs) and long-
acting b2-agonists (LABAs), are central to the
maintenance treatment of patients with
moderate to very severe chronic obstructive
pulmonary disease (COPD) [1]. The once-daily
LAMA tiotropium is well established in the
treatment of COPD and improves the main
functional and patient-orientated outcomes of
the disease [2–7]. Olodaterol is a novel once-
daily LABA that provides 24-h bronchodilation
[8–11], symptomatic benefit [12], and enhanced
exercise capacity [13]. Tiotropium ? olodaterol
has recently been evaluated in a phase III
program to determine its efficacy in the
treatment of COPD [14, 15].
International guidelines indicate that
combining bronchodilators of different
pharmacologic classes may improve efficacy
and reduce the risk of side effects, rather than
increasing the dose of a single bronchodilator.
The introduction of combination products
raises questions regarding the timing of their
initiation during the course of COPD, with
recent data indicating the potential benefits of
earlier pharmacologic intervention with
combination bronchodilator medications [16–
20].
The pivotal phase III trials TONADO-1 and -2
have demonstrated that once-daily
tiotropium ? olodaterol significantly improved
lung function and health-related quality of life
compared to the monocomponents over 1 year
in patients with moderate to very severe COPD
[14]. These studies were notable in that they
included a higher proportion of patients with
more severe disease (Global initiative for
chronic Obstructive Lung Disease [GOLD] 3
and 4) compared to previously reported studies
of other LAMA and LABA combinations such as
indacaterol ? glycopyrronium [21, 22], and
thus studied a broader population with respect
to disease severity.
While significant responses were observed in
the overall population of TONADO, evaluating
the effectiveness of tiotropium ? olodaterol in
specific subgroups of patients is of clear interest
to help inform health care providers. This is
particularly pertinent in light of the fact that in
clinical practice the population of patients with
COPD is heterogeneous with respect to factors
such as severity of disease, age, and concurrent
COPDmedication usage. The large nature of the
TONADO studies offers the opportunity to
study such subgroups. This post hoc analysis
of the efficacy data from TONADO-1 and -2 was
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conducted to help understand these points,
considering the effectiveness of
tiotropium ? olodaterol across COPD disease
severities, in patients with or without prior
bronchodilator or inhaled corticosteroid (ICS)
use, and according to patients’ age and sex. As
this analysis is post hoc, all P values and
confidence intervals are nominal.
METHODS
Study Design
Two replicate, multinational, phase III,
randomized, double-blind, active-controlled
trials were conducted to evaluate the efficacy
and safety of tiotropium ? olodaterol in
comparison to the monotherapy components
(TONADO-1, Study 1237.5: NCT01431274;
TONADO-2, Study 1237.6: NCT01431287)
(Fig. 1).
After a screening visit and 2-week baseline
period, patients were randomized to receive
tiotropium ? olodaterol (2.5/5 or 5/5 lg) or the
individual components as monotherapy
(tiotropium 2.5 or 5 lg, or olodaterol 5 lg) via
the Respimat Soft MistTM inhaler (Boehringer
Ingelheim, Ingelheim am Rhein, Germany) for
52 weeks. Due to the length of therapy and the
severity of disease studied, placebo was not used
as a treatment arm in these studies. Patients
Fig. 1 Study design (Study 1237.5: NCT01431274; Study
1237.6: NCT01431287). R randomization, FDC ﬁxed-
dose combination, QD once daily
Fig. 2 Key inclusion and exclusion criteria. COPD chronic obstructive pulmonary disease, GOLD Global initiative for
chronic Obstructive Lung Disease, FEV1 forced expiratory volume in 1 s
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receiving ICS at the start of the study could
continue with their medication and all patients
were provided with salbutamol/albuterol
metered-dose inhaler (100 lg per actuation) as
rescue medication, as required during the trial.
Patients receiving a LAMA or LABA prior to the
study were required to discontinue these
medications during screening. The studies
Table 1 Demographic and baseline patient characteristics (treated population): combined data for patients without prior













GOLD 2 (n = 1148)
Participants, n 238 231 240 211 228
Male, n (%) 171 (71.8) 161 (69.7) 160 (66.7) 156 (73.9) 148 (64.9)
Mean (SD) age, years 63.6 (8.5) 63.2 (8.9) 62.5 (8.9) 64.4 (8.2) 63.0 (8.2)
Current smoker, n (%) 107 (45.0) 116 (50.2) 112 (46.7) 88 (41.7) 111 (48.7)
Post-bronchodilator screening
Mean (SD) FEV1, mL 1773 (483) 1785 (478) 1765 (474) 1769 (441) 1716 (435)
Mean (SD) change from pre- to post-
bronchodilator FEV1, mL
172 (174) 210 (188) 184 (163) 202 (160) 175 (156)
Mean (SD) FEV1/FVC, % 52.6 (8.5) 52.7 (8.6) 54.5 (8.7) 53.0 (8.8) 54.2 (8.7)
Mean (SD) % of predicted normal
FEV1
63.4 (8.2) 63.5 (8.1) 63.1 (8.4) 63.9 (8.3) 63.2 (8.8)
GOLD 3–4 (n = 973)
Participants, n 179 199 213 184 198
Male, n (%) 144 (80.4) 161 (80.9) 178 (83.6) 142 (77.2) 143 (72.2)
Mean (SD) age, years 63.0 (7.8) 62.3 (8.1) 62.7 (8.7) 63.1 (7.4) 62.4 (8.4)
Current smoker, n (%) 82 (45.8) 78 (39.2) 63 (29.6) 77 (41.8) 74 (37.4)
Post-bronchodilator screening
Mean (SD) FEV1, mL 1010 (292) 1022 (291) 1047 (286) 1052 (314) 996 (284)
Mean (SD) change from pre- to post-
bronchodilator FEV1, mL
145 (116) 140 (136) 145 (118) 157 (111) 139 (163)
Mean (SD) FEV1/FVC, % 37.9 (9.3) 37.3 (9.6) 38.3 (10.3) 37.3 (8.6) 39.2 (10.2)
Mean (SD) % of predicted normal
FEV1
36.5 (8.8) 36.4 (8.5) 36.8 (8.5) 37.5 (8.8) 36.4 (8.6)
LAMA long-acting muscarinic antagonists, LABA long-acting b2-agonist, GOLD Global initiative for chronic Obstructive
Lung Disease, SD standard deviation, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
a Based on post-bronchodilator FEV1 percentage predicted
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included outpatients aged C40 years with a
history of moderate to very severe COPD
(GOLD 2–4). Key inclusion and exclusion
criteria are detailed in Fig. 2.
End Points
The primary spirometry end points were
evaluated after 24 weeks of treatment as
Table 2 Demographic and baseline patient characteristics (treated population): combined data for patients with prior













GOLD 2 (n = 1140)
Participants, n 294 287 277 308 274
Male, n (%) 201 (68.4) 202 (70.4) 180 (65.0) 210 (68.2) 202 (73.7)
Mean (SD) age, years 65.4 (8.0) 65.3 (9.1) 64.8 (8.7) 64.7 (8.2) 65.3 (8.9)
Current smoker, n (%) 87 (29.6) 102 (35.5) 98 (35.4) 107 (34.7) 98 (35.8)
Post-bronchodilator screening
Mean (SD) FEV1, mL 1693 (398) 1701 (401) 1685 (446) 1674 (409) 1690 (440)
Mean (SD) change from pre- to post-
bronchodilator FEV1, mL
203 (144) 191 (144) 196 (170) 195 (151) 201 (151)
Mean (SD) FEV1/FVC, % 52.4 (8.5) 52.5 (8.4) 51.3 (8.7) 50.9 (9.2) 51.2 (8.7)
Mean (SD) % of predicted normal
FEV1
62.9 (8.0) 62.2 (8.3) 62.7 (8.1) 61.6 (7.8) 62.0 (7.4)
GOLD 3–4 (n = 1597)
Participants, n 327 313 302 326 329
Male, n (%) 248 (75.8) 228 (72.8) 237 (78.5) 249 (76.4) 240 (72.9)
Mean (SD) age, years 64.3 (8.2) 64.5 (8.2) 64.9 (7.8) 64.0 (7.3) 64.0 (7.7)
Current smoker, n (%) 102 (31.2) 92 (29.4) 96 (31.8) 99 (30.4) 117 (35.6)
Post-bronchodilator screening
Mean (SD) FEV1, mL 1005 (288) 1057 (298) 993 (277) 1048 (295) 1008 (277)
Mean (SD) change from pre- to post-
bronchodilator FEV1, mL
145 (124) 155 (122) 154 (120) 155 (118) 142 (120)
Mean (SD) FEV1/FVC, % 36.8 (8.6) 37.6 (8.8) 36.4 (8.7) 37.1 (8.8) 37.3 (8.8)
Mean (SD) % of predicted normal
FEV1
36.8 (8.2) 38.3 (7.7) 36.2 (8.5) 37.8 (8.2) 37.0 (8.1)
LAMA long-acting muscarinic antagonists, LABA long-acting b2-agonist, GOLD Global initiative for chronic Obstructive
Lung Disease, SD standard deviation, FEV1 forced expiratory volume in 1 s, FVC forced vital capacity
a Based on post-bronchodilator FEV1 percentage predicted
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follows: forced expiratory volume in 1 s (FEV1)
area under the curve from 0 to 3 h (AUC0–3) and
trough FEV1 responses (i.e., change from
baseline to 24 weeks). Details of all
assessments performed, end points evaluated,
statistical methodology, and primary results for
these studies have been reported previously
[14].
Statistical Methods
In this analysis, FEV1 AUC0–3 and trough FEV1
were evaluated according to the following
subgroups: patients without prior LAMA or
LABA treatment at baseline or patients with
prior LAMA or LABA treatment at baseline.
Within each category of prior LAMA/LABA use,
analyses were split according to whether
patients had GOLD 2 (predicted FEV1 50% to
\80%) or GOLD 3 (30% to \50%)/4 (\30%)
COPD at baseline.
Pooled data from TONADO-1 and -2 were
used in this analysis. Mean changes from
baseline to 24 weeks were analyzed using a
mixed-effect model repeated measures
approach, including the fixed, categorical
effects of treatment, test day, and treatment-
by-test-day interaction, as well as the
continuous, fixed covariates of baseline and
baseline-by-test-day interaction. A spatial power
covariance structure was used to model within-
patient errors. The Kenward–Roger
approximation was used to estimate
denominator degrees of freedom.
In addition, pooled FEV1 AUC0–3 and trough
FEV1 responses at 24 weeks were analyzed
according to patients’ age (\65, 65 to\75, and
75 to\85 years), sex, and ICS usage using the
model described above. These data are
presented as forest plots, generated with SAS
Version 9.2 (SAS Institute Inc., Cary, NC, USA).
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
Fig. 3 Adjusted mean FEV1 AUC0–3 responses at
24 weeks; pooled data from TONADO-1 and -2.
a Patients without prior LAMA or LABA use;
b patients with prior LAMA or LABA use. FEV1 forced
expiratory volume in 1 s, AUC0–3 area under the curve
from 0 to 3 h, LAMA long-acting muscarinic antagonist,
LABA long-acting b2-agonist, SE standard error,
O olodaterol, T tiotropium, GOLD Global initiative for
chronic Obstructive Lung Disease
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RESULTS
Patient Disposition and Baseline
Characteristics
A total of 5163 patients were randomized, of
whom 5162 received study treatment (2624
Study 1237.5; 2538 Study 1237.6). The
baseline characteristics of patients are
presented in Tables 1 and 2 based on prior
LAMA or LABA maintenance treatment for
COPD and GOLD stage.
Overall baseline characteristics were similar
across maintenance-treatment subgroups. Lung
function in patients with GOLD 2 disease did
tend to be slightly better in those who did not
Table 3 Adjusted mean (SE) FEV1 AUC0–3 and trough FEV1 responses (i.e., change from baseline) after 24 weeks of






95% CI P value Adjusted mean (SE)
trough FEV1, mL




versus olodaterol 5 lg 127 (19) 90, 164 \0.0001 82 (20) 43, 120 \0.0001
versus tiotropium 5 lg 114 (19) 77, 151 \0.0001 79 (20) 40, 118 \0.0001
Tiotropium ? olodaterol
2.5/5 lg
versus olodaterol 5 lg 98 (19) 61, 136 \0.0001 66 (20) 26, 105 0.0012
versus tiotropium 2.5 lg 108 (19) 70, 146 \0.0001 71 (20) 31, 111 0.0005




versus olodaterol 5 lg 134 (19) 96, 171 \0.0001 92 (20) 53, 131 \0.0001
versus tiotropium 5 lg 114 (18) 79, 150 \0.0001 69 (19) 32, 106 0.0002
Tiotropium ? olodaterol
2.5/5 lg
versus olodaterol 5 lg 120 (19) 82, 159 \0.0001 53 (20) 13, 92 0.0091
versus tiotropium 2.5 lg 117 (19) 80, 154 \0.0001 44 (20) 6, 83 0.0237
versus tiotropium 5 lg 101 (19) 65, 137 \0.0001 30 (19) -8, 67 0.1237
Adjustedmean (SE) obtained fromﬁtting amixedmodel for repeatedmeasurements including ﬁxed effects of treatment, planned
test day, treatment-by-test-day interaction, baseline, and baseline-by-test-day interaction; patient as a randomeffect; spatial power
covariance structure for within-patient errors and Kenward–Roger approximation of denominator degrees of freedom
SE standard error, FEV1 forced expiratory volume in 1 s, AUC0–3 area under the curve from 0 to 3 h, LAMA long-acting
muscarinic antagonist, LABA long-acting b2-agonist, CI conﬁdence interval, GOLD Global initiative for chronic
Obstructive Lung Disease
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receive prior LAMA or LABA maintenance
treatment than in those who received
maintenance therapies before the study. In
addition, more patients who received prior
LAMA or LABA maintenance treatment were
also taking ICS than those without prior
maintenance treatment.
Efficacy
Patients Without Prior LAMA or LABA
Maintenance Treatment
In each treatment group, FEV1 AUC0–3 responses
(i.e., change from baseline) were greater in
patients with GOLD 2 disease than GOLD 3–4
disease (Fig. 3a; Table S1 in the electronic
supplementary material). In both of the GOLD
subgroups, FEV1 AUC0–3 responses were greater
with both doses of tiotropium ? olodaterol than
the monotherapy components at Week 24, and
differences were statistically significant for all
comparisons analyzed (Table 3).
Trough FEV1 responses were consistently
greater with both doses of
tiotropium ? olodaterol than the monotherapy
components; no obvious trend was apparent
between patients with GOLD 2 and GOLD 3–4
COPD (Fig. 4a). While all differences between
the various monotherapies and tiotropium ?
olodaterol 5/5 lg were statistically significant in
patients with GOLD 2 COPD, in GOLD 3–4
COPD patients receiving tiotropium ?
olodaterol 2.5/5 lg the differences were not as
robust, such that changes in trough FEV1 with
tiotropium 5 lg were not significantly different
from tiotropium ? olodaterol 2.5/5 lg (Table 3).
Patients Receiving Prior LAMA or LABA
Maintenance Treatment
In patients who received prior maintenance
treatment, as in patients without prior LAMA or
LABA maintenance bronchodilator therapy, the
FEV1 AUC0–3 responses for the individual
treatments were greater in those with less severe
COPD (Fig. 3b; Table S2 in the electronic
Fig. 4 Adjusted mean trough FEV1 responses at 24 weeks;
pooled data from TONADO-1 and -2. a Patients without
prior LAMA or LABA use; b patients with prior LAMA
or LABA use. FEV1 forced expiratory volume in 1 s,
LAMA long-acting muscarinic antagonist, LABA long-
acting b2-agonist, SE standard error, O olodaterol,
T tiotropium, GOLD Global initiative for chronic
Obstructive Lung Disease
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supplementary material). Again, FEV1 AUC0–3
responses were greater with both doses of
tiotropium ? olodaterol than the monotherapy
components and all comparisons were
statistically significant (P\0.001).
Trough FEV1 responses were consistently
greater with both doses of tiotropium ?
olodaterol than the monotherapy components
and were generally greater in patients with less
severe COPD (with the exception of
tiotropium ? olodaterol 2.5/5 lg) (Fig. 4b). All
comparisons between tiotropium ? olodaterol
and the monotherapies were statistically
significant in patients with GOLD 3–4 COPD;
Table 4 Adjusted mean (SE) FEV1 AUC0–3 and trough FEV1 responses (i.e., change from baseline) after 24 weeks of
treatment (full analysis set): combined data for patients with prior LAMA or LABA treatment at baseline: treatment
differences
Treatment comparison Adjusted mean (SE)
FEV1 AUC0–3, mL
95% CI P value Adjusted mean (SE)
trough FEV1, mL




versus olodaterol 5 lg 136 (17) 102, 169 \0.0001 85 (18) 50, 121 \0.0001
versus tiotropium 5 lg 123 (17) 89, 157 \0.0001 61 (18) 26, 97 0.0007
Tiotropium ? olodaterol
2.5/5 lg
versus olodaterol 5 lg 102 (17) 69, 135 \0.0001 43 (17) 9, 77 0.0133
versus tiotropium 2.5 lg 113 (17) 81, 146 \0.0001 25 (17) -9, 59 0.1567




versus olodaterol 5 lg 119 (14) 92, 146 \0.0001 83 (13) 57, 109 \0.0001
versus tiotropium 5 lg 95 (14) 68, 122 \0.0001 41 (14) 15, 68 0.0023
Tiotropium ? olodaterol
2.5/5 lg
versus olodaterol 5 lg 134 (14) 107, 162 \0.0001 85 (14) 58, 111 \0.0001
versus tiotropium 2.5 lg 107 (14) 80, 134 \0.0001 45 (14) 18, 71 0.0010
versus tiotropium 5 lg 110 (14) 83, 138 \0.0001 43 (14) 16, 70 0.0016
Adjusted mean (SE) obtained from ﬁtting a mixed model for repeated measurements including ﬁxed effects of treatment,
planned test day, treatment-by-test-day interaction, baseline, and baseline-by-test-day interaction; patient as a random effect;
spatial power covariance structure for within-patient errors and Kenward–Roger approximation of denominator degrees of
freedom
SE standard error, FEV1 forced expiratory volume in 1 s, AUC0–3 area under the curve from 0–3 h, LAMA long-acting
muscarinic antagonist, LABA long-acting b2-agonist, CI conﬁdence interval, GOLD Global initiative for chronic
Obstructive Lung Disease
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however, the comparisons between
tiotropium ? olodaterol 2.5/5 lg and
tiotropium 2.5 or 5 lg in patients with GOLD
2 COPD did not achieve statistical significance
(Table 4).
Other Patient Subgroups
FEV1 AUC0–3 and trough FEV1 responses at
24 weeks are presented by age, sex, and prior
ICS usage in Figs. 5 and 6. These show that
tiotropium ? olodaterol was more effective
than the monotherapy components across all
of the subgroups analyzed, with the exception
of trough FEV1 (tiotropium ? olodaterol 5/5 lg
versus tiotropium 5 lg) in patients aged
75–85 years.
DISCUSSION
In all the patient subgroups included in this
analysis of pooled data from the TONADO-1
and -2 studies, tiotropium ? olodaterol
consistently resulted in greater improvements
in lung function than the monotherapy
components, as determined by FEV1 AUC0–3
and trough FEV1 responses at 24 weeks. These
results are in line with data from other studies
using a LAMA and a LABA, and further
Fig. 5 Forest plots for FEV1 AUC0–3 responses at
24 weeks. a Tiotropium ? olodaterol 5/5 lg versus
olodaterol 5 lg; b tiotropium ? olodaterol 5/5 lg versus
tiotropium 5 lg. FEV1 forced expiratory volume in 1 s,
AUC0–3 area under the curve from 0 to 3 h, ICS inhaled
corticosteroid
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highlight the benefits of combined
bronchodilation over monotherapy treatment
[23–25]. Of particular note, tiotropium ?
olodaterol 5/5 lg once daily improved lung
function in patients with GOLD 2 and 3–4
disease, and there were no apparently relevant
differences in lung-function responses
according to whether these patients had or
had not received prior maintenance therapy
with a LAMA or a LABA.
While no statistical comparisons were made
between subgroups, it was apparent that both
FEV1 AUC0–3 and trough FEV1 responses for the
individual treatments were, in general, greater
in patients with less severe disease. The greater
lung-function responses observed in patients
with GOLD 2 COPD in our studies are in line
with other clinical trials, including the 4-year
study of tiotropium (UPLIFT; NCT00144339)
[18]. While patients are less symptomatic earlier
in their disease course, recent data have
suggested that the progression of early COPD
occurs at a faster rate than during the later
stages of disease [16, 17]. In addition, the
UPLIFT study suggested a possible reduction in
the rate of decline of post-bronchodilator FEV1
in patients with GOLD 2 COPD using
tiotropium [18]. As more information becomes
Fig. 6 Forest plots for trough FEV1 responses at 24 weeks.
a Tiotropium ? olodaterol 5/5 lg versus olodaterol 5 lg;
b tiotropium ? olodaterol 5/5 lg versus tiotropium 5 lg.
FEV1 forced expiratory volume in 1 s, ICS inhaled
corticosteroid
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available related to the response of symptoms,
lung function, and exacerbations to good
maintenance bronchodilator therapy in COPD
patients with less severe disease, opinion is
moving towards using effective bronchodilation
in the earlier stages of COPD [18, 26].
Our data support the use of dual-action
maintenance bronchodilator therapy with
LAMA ? LABA for treatment-naive and less
severe COPD, as well as those more severe
patients already receiving maintenance
therapies. Both doses of
tiotropium ? olodaterol were more effective
than the monotherapy components in all
subgroups analyzed, although the lower dose
of the combination (2.5/5 lg) may have been
slightly less effective in providing trough
bronchodilation in less severe, treatment-naive
patients. In addition, it appeared that the FEV1
AUC0–3 responses were somewhat greater in
younger patients than older patients, a finding
that may reflect more the greater response in
the less severe patients rather than a primary
age effect. Otherwise, no major differences in
responses were observed between treatment
groups.
Our analysis does have some limitations in
so far as it was post hoc and no direct statistical
comparisons could be made between subgroups.
However, based on the fact that data were
pooled from two large phase III studies, the
subgroups were all sizeable (each comprising
[900 patients), allowing a clear evaluation of
the effects of tiotropium ? olodaterol in
comparison to the monotherapy components.
CONCLUSIONS
Tiotropium ? olodaterol 5/5 lg resulted in
improved lung-function responses compared
to the monotherapy components across all
subgroups analyzed. These data show that
tiotropium ? olodaterol is effective in patients
irrespective of age, disease severity, and prior
treatment with bronchodilators and/or ICS.
The improvements from baseline in lung
function were greater in patients with less
severe disease, adding support for the use of
combination bronchodilation earlier in the
course of COPD.
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